↓ Skip to main content

CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis

Overview of attention for article published in Journal of Neuroinflammation, January 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 X users

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Published in
Journal of Neuroinflammation, January 2014
DOI 10.1186/1742-2094-11-18
Pubmed ID
Authors

Soraya Maria Menezes, Daniele Decanine, David Brassat, Ricardo Khouri, Saul V Schnitman, Ramon Kruschewsky, Giovanni López, Carolina Alvarez, Michael Talledo, Eduardo Gotuzzo, Anne-Mieke Vandamme, Bernardo Galvão-Castro, Roland Liblau, Johan Van Weyenbergh

Abstract

Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 58 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 19%
Student > Ph. D. Student 10 17%
Student > Bachelor 7 12%
Student > Master 7 12%
Student > Doctoral Student 6 10%
Other 12 20%
Unknown 6 10%
Readers by discipline Count As %
Medicine and Dentistry 22 37%
Immunology and Microbiology 10 17%
Agricultural and Biological Sciences 9 15%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Engineering 2 3%
Other 6 10%
Unknown 8 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2021.
All research outputs
#13,401,381
of 22,741,406 outputs
Outputs from Journal of Neuroinflammation
#1,440
of 2,617 outputs
Outputs of similar age
#162,826
of 308,137 outputs
Outputs of similar age from Journal of Neuroinflammation
#30
of 62 outputs
Altmetric has tracked 22,741,406 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,617 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,137 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.